Acute Myocardial Infarction Revealing a Polycythemia Vera: A Case Report

Y. Hamine *

Department of Cardiology, Ibn Rochd Hospital University, Casablanca, Morocco.

T. Ettachfini

Department of Cardiology, Ibn Rochd Hospital University, Casablanca, Morocco.

A. Elamraoui

Department of Cardiology, Ibn Rochd Hospital University, Casablanca, Morocco.

M. Rochd

Department of Cardiology, Ibn Rochd Hospital University, Casablanca, Morocco.

M. G. Bennouna

Department of Cardiology, Ibn Rochd Hospital University, Casablanca, Morocco.

R. Habbal

Department of Cardiology, Ibn Rochd Hospital University, Casablanca, Morocco.

*Author to whom correspondence should be addressed.


Abstract

Acute myocardial infarction is usually seen in the setting of atherosclerosis and its associated risk factors. One of the rare causes of AMI in young patients is polycythemia vera.

We report the case of 38-year-old male with a history of tobacco use, who presented with constrictive chest pain and ST segment elevation in leads V1 through V6, DI and AvL. His blood investigation report showed higher levels of hemoglobin and hematocrit. the search for the JAK2V617F mutation in the blood came back positive. The patient was diagnosed with polycythemia vera.

This case illustrates the importance of considering PV a cardiovascular risk factor, making early diagnosis crucial for early initiation of preventive treatment.

Keywords: Polycythemia vera, myocardial infarction, JAK2 mutation


How to Cite

Hamine , Y., T. Ettachfini, A. Elamraoui, M. Rochd, M. G. Bennouna, and R. Habbal. 2023. “Acute Myocardial Infarction Revealing a Polycythemia Vera: A Case Report”. Asian Journal of Cardiology Research 6 (1):173-78. https://journalajcr.com/index.php/AJCR/article/view/154.

Downloads

Download data is not yet available.

References

Bahbahani H, Aljenaee K, Bella A. Polycythemia vera presenting as acute myocardial infarction: An unusual presentation. J. Saudi Heart Assoc. 2015;27:57–60.

Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021;35:3339–3351.

Gulati R, et al. Acute myocardial infarction in young individuals. Mayo Clin. Proc. 2020;95:136–156.

Bădulescu OV, Ciocoiu M, Bararu I, Mocanu M, Bădescu M. Polycythemia vera syndrome--as a protrombothic state. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2014; 118:432–438.

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues – IARC.

Available:https://www.iarc.who.int/news-events/who-classification-of-tumours-of-haematopoietic-and-lymphoid-tissues-2/.

Durmus A, et al. The thrombotic events in polycythemia vera patients may be related to increased oxidative stress. Med. Princ. Pract. Int. J. Kuwait Univ. Health Sci. Cent. 2014;23:253–258.

Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br. J. Haematol. 2005;128:275–290.

Rossi C, Randi ML, Zerbinati P, Rinaldi V, Girolami A. Acute coronary disease in essential thrombocythemia and polycythemia vera. J. Intern. Med. 1998; 244:49–53.

Lim Y, et al. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thrombosis Research. 2015;135:846-851.

Malak S, et al. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cells. Mol. Dis. 2012;49:170–176.

Hermanns B, Handt S, Kindler J, Füzesi L. Coronary vasculopathy in polycythemia vera. Pathol. Oncol. Res. POR. 1998;4:37–39.

Wasserman LR, et al. Influence of therapy on causes of death in polycythemia vera. Trans. Assoc. Am. Physicians. 1981;94: 30–38.

Landolfi R, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med. 2004;350:114–124.

Barosi G, et al. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia. 2015;29:20–26.

Forsyth CJ, et al. Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms. Intern. Med. J. 2019;49:948–954.

Passamonti F. How I treat polycythemia vera. Blood. 2012;120:275–284.

Gerds AT, Dao KH. Polycythemia vera management and challenges in the community health setting. Oncology. 2017;92:179–189.

Ibanez B, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2018;39:119–177.

Okabe H, et al. Acute myocardial infarction following sequential multi- vessel occlusion in a case of polycythemia vera. J. Cardiol. Cases. 2019 ;20:111– 114.